[go: up one dir, main page]

MX9606635A - Compuestos y metodos para el tratamiento de desordenes cardiovasculares, inflamatorios e inmunes. - Google Patents

Compuestos y metodos para el tratamiento de desordenes cardiovasculares, inflamatorios e inmunes.

Info

Publication number
MX9606635A
MX9606635A MX9606635A MX9606635A MX9606635A MX 9606635 A MX9606635 A MX 9606635A MX 9606635 A MX9606635 A MX 9606635A MX 9606635 A MX9606635 A MX 9606635A MX 9606635 A MX9606635 A MX 9606635A
Authority
MX
Mexico
Prior art keywords
compounds
inflammatory
lipoxygenase
cardiovascular
treatment
Prior art date
Application number
MX9606635A
Other languages
English (en)
Inventor
Xiong Cai
Grewal Grewal
Sajjat Hussoin
Aberra Fura
Ralph Scannell
Tesfaye Biftu
Changgeng Qian
Original Assignee
Cytomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/265,656 external-priority patent/US5792776A/en
Priority claimed from US08/390,641 external-priority patent/US6201016B1/en
Priority claimed from US08/454,600 external-priority patent/US5750565A/en
Priority claimed from US08/454,748 external-priority patent/US5703093A/en
Application filed by Cytomed Inc filed Critical Cytomed Inc
Publication of MX9606635A publication Critical patent/MX9606635A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se exponen tetrahidrofuranos, tetrahidrotiofenos, pirrolidona y ciclopentanos que reducen la quimiotaxis y ráfagas respiratorias que conducen a la formacion de radicales de oxígeno dañinos de leucocitos polimorfonucleares durante una respuesta inflamatoria o inmune. Los compuestos de PAF, al inhibir la encima de 5-lipoxigenasa, o al exhibir doble actividad, es decir al actuar tanto como antagonista receptor de PAF como inhibidor de 5-lipoxigenasa. Se ha determinado que la actividad, disponibilidad oral y estabilidad in vivo (por ejemplo, proporcion de glucoronidacion) de la 5-lipoxigenasa puede variar significativamente entre los isomeros opticos de los compuestos expuestos.
MX9606635A 1994-06-27 1995-06-27 Compuestos y metodos para el tratamiento de desordenes cardiovasculares, inflamatorios e inmunes. MX9606635A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/265,656 US5792776A (en) 1994-06-27 1994-06-27 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US08/390,641 US6201016B1 (en) 1994-06-27 1995-02-17 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US08/454,600 US5750565A (en) 1995-05-25 1995-05-25 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US08/454,748 US5703093A (en) 1995-05-31 1995-05-31 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
PCT/US1995/008213 WO1996000212A1 (en) 1994-06-27 1995-06-27 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders

Publications (1)

Publication Number Publication Date
MX9606635A true MX9606635A (es) 1997-12-31

Family

ID=27500861

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9606635A MX9606635A (es) 1994-06-27 1995-06-27 Compuestos y metodos para el tratamiento de desordenes cardiovasculares, inflamatorios e inmunes.

Country Status (17)

Country Link
EP (1) EP0770064B1 (es)
KR (1) KR100276570B1 (es)
CN (1) CN1151125C (es)
AT (1) ATE253564T1 (es)
AU (1) AU703756B2 (es)
BR (1) BR9508196A (es)
CA (1) CA2194064C (es)
CZ (1) CZ372096A3 (es)
DE (1) DE69532077T2 (es)
EE (1) EE9600184A (es)
FI (1) FI965123A7 (es)
HU (1) HUT77773A (es)
MX (1) MX9606635A (es)
NO (1) NO965569L (es)
PL (1) PL317873A1 (es)
RU (1) RU2190607C2 (es)
WO (1) WO1996000212A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08502243A (ja) 1992-07-13 1996-03-12 サイトメッド，インコーポレイテッド 炎症性および免疫性疾患の治療のための２，５‐ジアリールテトラヒドロ‐チオフェン、‐フランおよび類似体
US5463083A (en) * 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5434151A (en) * 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5750565A (en) * 1995-05-25 1998-05-12 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5792776A (en) * 1994-06-27 1998-08-11 Cytomed, Inc., Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5703093A (en) * 1995-05-31 1997-12-30 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
AU3370099A (en) * 1998-03-31 1999-10-18 Mayo Foundation For Medical Education And Research Use of platelet activating factor (paf) inhibitors to inhibit il-5 induced eosinophil activation or degranulation
CN1313857A (zh) 1998-07-03 2001-09-19 千年药物公司 取代的四氢呋喃化合物的合成方法
AU4966199A (en) 1998-07-03 2000-01-24 Millennium Pharmaceuticals, Inc. Substituted oxygen alicyclic compounds, including methods for synthesis thereof
US6255498B1 (en) 1998-10-16 2001-07-03 Millennium Pharmaceuticals, Inc. Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans
ATE547101T1 (de) 2000-08-04 2012-03-15 Dmi Biosciences Inc Verfahren zur verwendung von diketopiperazinen und zusammensetzungen, die diese enthalten
NZ539735A (en) 2002-10-02 2009-07-31 Dmi Biosciences Inc Diagnosis and monitoring of diseases using markers, such as diketopiperazines
ATE479683T1 (de) 2002-11-05 2010-09-15 Glaxo Group Ltd Antibakterielle mittel
RU2217141C1 (ru) * 2002-11-20 2003-11-27 Балавадзе Михаил Элизбарович Состав "витализин-1" для профилактики атеросклероза, сердечно-сосудистых заболеваний и поддерживающей терапии вирусных заболеваний
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
ES2579635T3 (es) 2003-05-15 2016-08-12 Ampio Pharmaceuticals, Inc. Tratamiento de enfermedades mediadas por los linfocitos T
US7307064B2 (en) * 2003-08-04 2007-12-11 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble CTLA4 molecule
MXPA06008599A (es) * 2004-01-30 2006-08-28 Schering Corp Polimorfos cristalinos de un ligando receptor de cxc-quimiocina.
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
EP3721884A1 (en) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
JP2014530063A (ja) 2011-10-10 2014-11-17 アンピオ ファーマシューティカルズ，インコーポレイテッド 免疫寛容が高められた埋込み型医療用デバイス、ならびに製造方法および埋込み方法
BR112014008036A2 (pt) 2011-10-28 2017-04-11 Ampio Pharmaceuticals Inc tratamento de rinite
EP2968315B1 (en) 2013-03-15 2020-06-03 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
KR101480674B1 (ko) * 2014-07-03 2015-01-09 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
KR101503647B1 (ko) 2014-07-03 2015-03-18 주식회사 큐리언트 염증성 질환 치료용 약학적 조성물
KR101496095B1 (ko) * 2014-07-04 2015-03-03 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
KR101496094B1 (ko) 2014-07-04 2015-02-25 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
KR101496096B1 (ko) * 2014-07-17 2015-03-02 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
WO2016028790A1 (en) 2014-08-18 2016-02-25 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ211146A (en) * 1984-02-29 1987-10-30 Merck & Co Inc 2,5-diaryl-tetrahydrothiophene derivatives and pharmaceutical compositions
US4757084A (en) * 1984-02-29 1988-07-12 Merck & Co., Inc. 2,5-diaryl tetrahydrothiophenes and analogs thereof as PAF-antagonists
US4604407A (en) * 1985-04-04 1986-08-05 E. R. Squibb & Sons, Inc. Hydroxamates
DE3778248D1 (de) * 1986-08-21 1992-05-21 Merck & Co Inc 1,3-diarylcyclopentane und deren abkoemmlinge als paf-antagonisten.
US4873259A (en) * 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
US4996203A (en) * 1987-12-21 1991-02-26 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
EP0365089A3 (en) * 1988-10-18 1991-06-05 Merck & Co. Inc. 2-aryl-5(3-methoxy-5-(hydroxypropylsulfonyl)-4-propoxyphenyl) tetrahydrothiophen and analogs
US5175183A (en) * 1989-02-01 1992-12-29 Abbott Laboratories Lipoxygenase inhibiting compounds
US4977146A (en) * 1989-06-08 1990-12-11 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
US5037853A (en) * 1989-12-28 1991-08-06 Abbott Laboratories Cyclopropyl derivative lipoxygenase inhibitors
GB9009469D0 (en) * 1990-04-27 1990-06-20 British Bio Technology Compounds
CA2045863A1 (en) * 1990-06-29 1991-12-30 Ichiro Shinkai Process of making 2,5-diaryl tetrahydrofurans and analogs thereof useful as paf antagonists
US5244896A (en) * 1990-09-14 1993-09-14 Marion Merrell Dow Inc. Carbocyclic adenosine analogs useful as immunosuppressants
US5110831A (en) * 1990-11-30 1992-05-05 Du Pont Merck Pharmaceutical Company Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
JPH0730061B2 (ja) * 1991-02-07 1995-04-05 ファイザー製薬株式会社 ヒドロキサム酸誘導体および組成物
US5420164A (en) * 1991-04-04 1995-05-30 Yoshitomi Pharmaceutical Industries, Ltd. Cycloalkylurea compounds
US5183818A (en) * 1991-08-27 1993-02-02 Abbott Laboratories Arylalkylether and arylalkylthioether inhibitors of lipoxygenase enzyme activity
US5169854A (en) * 1992-02-26 1992-12-08 Abbott Laboratories N-substituted-furylalkenyl hydroxamic acid and N-hydroxyurea compounds having lipoxygenase inhibitory activity
US5187192A (en) * 1992-03-13 1993-02-16 Abbott Laboratories Cyclobutyl derivatives having lipoxygenase inhibitory activity
US5326787A (en) * 1992-05-12 1994-07-05 Abbott Laboratories Cycloalkyl N-hydroxy derivatives having lipoxygenase inhibitory activity
JPH08502243A (ja) * 1992-07-13 1996-03-12 サイトメッド，インコーポレイテッド 炎症性および免疫性疾患の治療のための２，５‐ジアリールテトラヒドロ‐チオフェン、‐フランおよび類似体
US5463083A (en) * 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5288751A (en) * 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
TW418089B (en) * 1993-08-19 2001-01-11 Pfizer Pharmaceutical composition comprising phenoxyphenyl cyclopentenyl hydroxyureas (the dextrorotary isomers)

Also Published As

Publication number Publication date
EP0770064B1 (en) 2003-11-05
NO965569L (no) 1997-02-17
ATE253564T1 (de) 2003-11-15
FI965123A7 (fi) 1997-02-26
FI965123A0 (fi) 1996-12-19
CZ372096A3 (cs) 1998-04-15
DE69532077D1 (de) 2003-12-11
EE9600184A (et) 1997-06-16
CN1163610A (zh) 1997-10-29
EP0770064A4 (en) 1998-01-14
CN1151125C (zh) 2004-05-26
BR9508196A (pt) 1997-09-02
RU2190607C2 (ru) 2002-10-10
DE69532077T2 (de) 2004-09-02
WO1996000212A1 (en) 1996-01-04
CA2194064C (en) 2009-03-17
CA2194064A1 (en) 1996-01-04
HUT77773A (hu) 1998-08-28
PL317873A1 (en) 1997-04-28
AU703756B2 (en) 1999-04-01
NO965569D0 (no) 1996-12-23
EP0770064A1 (en) 1997-05-02
HK1004396A1 (en) 1998-11-27
HU9603611D0 (en) 1997-02-28
KR100276570B1 (ko) 2001-02-01
AU2914295A (en) 1996-01-19

Similar Documents

Publication Publication Date Title
MX9606635A (es) Compuestos y metodos para el tratamiento de desordenes cardiovasculares, inflamatorios e inmunes.
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
IT8547664A0 (it) Composizione acquosa per il trattamento del cavo orale
IT8421516A0 (it) Composizioni migliorate per il trattamento della psoriasi.
IT1131678B (it) Sopporto ammortizzante per la sospensione di un corpo oscillante ad una struttura di sopporto
HUP9701068A2 (hu) Mirtazapint és egy vagy több szelektív szerotoninújrafelvétel-inhibitort tartalmazó gyógyászati készítmény
IL163026A (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
DK0650485T3 (da) 2,5-Diaryltetrahydrothiophener, -furaner og analoger til behandling af inflammatoriske forstyrrelser og immunforstyrrelser
IT8068790A0 (it) Composizione fotopolimerizzabile particolarmente per la produzionedi lastre da stampa
ATE415395T1 (de) Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen
ITMI932189A0 (it) Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta
ITMI911578A1 (it) Impiego del fosfatidilinositolo per la terapia dei disturbi della depressione.
IT7849227A0 (it) Procedimento per la separazione di pirrolidone-2 da polipirrolidone
FR2691066B1 (fr) Utilisation de glycosaminoglycanes exogenes, de leurs analogues ainsi que de leurs fragments, fractions et derives, pour la preparation de medicaments destines au traitement de thrombopenies.
IT8121568A0 (it) Prodotto utile per il trattamento della psoriasi.
IT8224214A0 (it) Procedimento per la preparazione di amminoalchil furani o tiofeni.
FR2813307B1 (fr) Aminoalkenylbenzoyl-benzofurannes ou benzothiophenes, leur procede de preparation et les compositions les contenant
ATE184155T1 (de) Verwendung der jodwasserstoffsäure als aphrodisiakum
WO2001044264A3 (de) Neue stromelysin inhibitoren
IT7848486A0 (it) Composizioni per il trattamento di infezioni da elminti
IT1169217B (it) Derivati 1-((2-mercaptocicloalchil)carbonil)-l-prolinici, il procedimento per la loro preparazione, gli intermedi della loro sintesi e il loro utilizzo come agenti anti-iper-tensivi
IT8121741A0 (it) Perfezionamenti ai filtri per la depurazione e disinfezione dei gascadaverici.
BE869942A (fr) Nouvelles compositions pour le traitement des affections atherosclerotiques
IT7827929A0 (it) Procedimento di purificazione di gas di riciclo contenenti ossigeno provenienti da una ozonizzazione.
RO70105A2 (ro) Solutie uleioasa pentru tratamentul afectiunilor mucoasei nazale